PubMed:20647473 / 871-1113 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T8","span":{"begin":0,"end":242},"obj":"Sentence"},{"id":"T8","span":{"begin":0,"end":242},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment with panobinostat induced heat shock protein 90 acetylation; depleted the levels of heat shock protein 90 client proteins, cyclin-dependent kinase 4, c-RAF, and AKT; and abrogated bortezomib-induced aggresome formation in MCL cells."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"20647473-4#171#174#gene207","span":{"begin":171,"end":174},"obj":"gene207"},{"id":"20647473-4#232#235#diseaseC0334634","span":{"begin":232,"end":235},"obj":"diseaseC0334634"},{"id":"20647473-4#232#235#diseaseC1708350","span":{"begin":232,"end":235},"obj":"diseaseC1708350"}],"relations":[{"id":"171#174#gene207232#235#diseaseC0334634","pred":"associated_with","subj":"20647473-4#171#174#gene207","obj":"20647473-4#232#235#diseaseC0334634"},{"id":"171#174#gene207232#235#diseaseC1708350","pred":"associated_with","subj":"20647473-4#171#174#gene207","obj":"20647473-4#232#235#diseaseC1708350"}],"text":"Treatment with panobinostat induced heat shock protein 90 acetylation; depleted the levels of heat shock protein 90 client proteins, cyclin-dependent kinase 4, c-RAF, and AKT; and abrogated bortezomib-induced aggresome formation in MCL cells."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T1685","span":{"begin":171,"end":174},"obj":"gene:207"},{"id":"T1686","span":{"begin":232,"end":235},"obj":"disease:C0334634"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T1685","obj":"T1686"},{"id":"R2","pred":"associated_with","subj":"T1685","obj":"T1686"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Treatment with panobinostat induced heat shock protein 90 acetylation; depleted the levels of heat shock protein 90 client proteins, cyclin-dependent kinase 4, c-RAF, and AKT; and abrogated bortezomib-induced aggresome formation in MCL cells."}